Trials / Completed
CompletedNCT02280473
A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Refresh Optive® Gel Drops | Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| DRUG | REFRESH LIQUIGEL® | REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
Timeline
- Start date
- 2014-11-13
- Primary completion
- 2015-03-16
- Completion
- 2015-03-16
- First posted
- 2014-10-31
- Last updated
- 2019-04-16
- Results posted
- 2017-06-07
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02280473. Inclusion in this directory is not an endorsement.